A5086752992- Colorectal Cancer Screening and Detection
- Gastric Cancer Management and Outcomes
- Inflammatory Bowel Disease
- Liver Diseases and Immunity
- Colorectal Cancer Surgical Treatments
- Viral-associated cancers and disorders
- Biosimilars and Bioanalytical Methods
- Gastrointestinal disorders and treatments
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Liver Disease Diagnosis and Treatment
- Global Cancer Incidence and Screening
- Immunodeficiency and Autoimmune Disorders
St. Vincent's University Hospital
2016-2025
University College Dublin
2016
Summary and Recommendation This statement conveys the European Society of Gastrointestinal Endoscopy (ESGE) position on use computer-aided detection (CADe) with artificial intelligence (AI) during colonoscopy for colorectal cancer (CRC) screening or surveillance. The ESGE is informed by BMJ Rapid initiative approach MAGIC Evidence Ecosystem Foundation; these include systematic reviews currently available evidence, supplemented microsimulation modeling patient values preferences, benefits...
Fecal immunochemical testing (FIT) positivity is determined by a threshold decided individual screening programs. Data are limited on correlation between FIT levels and pathology identified at colonoscopy. Our aim was to examine the in national colorectal cancer program.FIT (n = 9,271) were analyzed correlated with patient demographics identified, including adenomas, sessile serrated lesions, number/size of presence dysplasia. Levels divided into 2 categories: defined as "high" or "low"...
Colorectal cancer (CRC) screening is proven to reduce CRC-related mortality. Faecal immunochemical testing (FIT)-positive clients in the Irish National CRC Screening Programme underwent colonoscopy. Round 1 uptake was 40.2%. We sought identify barriers participation by assessing knowledge of and examining attitudes towards FIT test colonoscopy.Questionnaires based on a modified Champion's Health Belief Model were mailed 3500 invitees: 1000 FIT-positive, FIT-negative 1500 non-participants....
Background Approximately 150 IBD patients are currently on infliximab (IFX) at our centre, costing over €2 million in 2016. IFX drug and antibody level measurement was introduced 2015. Aim To analyse the clinical financial impact of levels antibodies to (ATI) Method with ATI measured between Dec 2015 2016 were identified from laboratory records an database. The results reaction recorded. Results 93 (55 Crohn’s, 38 UC) had checked. More than one made 25. 37 subtherapeutic ( 7 mg/ml): 12 dose...